Vir Biotechnology Q1 net loss $125.7 million; cash and investments $809.3 million
Vir Biotechnology reported a first-quarter 2026 net loss of $125.7 million, or $0.85 per share, compared with a net loss of $121.0 million, or $0.88 per share, a year earlier. Total revenues were negative $29 thousand, down from $3.0 million, while R&D and SG&A expenses both declined. The company said its cash, cash equivalents and investments were $809.3 million at March 31, 2026, and expects them to fund operations into the second half of 2028.
Key points
- Net loss was $125.7 million ($0.85 per share) for Q1 2026, versus $121.0 million ($0.88 per share) in Q1 2025.
- Total revenues were negative $29 thousand in Q1 2026, compared with $3.0 million in Q1 2025.
- R&D expenses fell to $108.9 million from $118.6 million, mainly due to a $30.0 million expense in Q1 2025 tied to the restated Alnylam agreement.
- The Astellas collaboration on VIR-5500 closed in April, with a combined upfront payment and equity investment of $315 million expected in Q2 2026.
The filing
Written by AI on Nov 8, 2026, 6:56 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on May 06, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.